Breast Cancer Drug Exemestane Comes Under the Scanner
A recent study has found that the daily intake of breast cancer drug called exemestane for almost five years reduces the bone mineral density (BMD) significantly. The loss of drug can’t be redeemed even if women are prescribed with vitamin D supplements along with the treatment.
The findings of the study have been published in the medical journal Lancet. The study was conducted by the Canadian researchers. According to them, the particular drug, exemestane leads to loss of cortical bone, which covers
80% of the human skeleton.
With the age, it is quite common for women to shed off some of the BMD but when women are taking exemestane then about 8% of the BMD is lost. Normally, a woman loses 1% of the BMD, when the consumption of the drug is absent.
The findings of the study throw light over the increased cases of fracture in the old age. As the bone become weak, elder people are more vulnerable of experiencing fracture. The lead author of the study, Angela Cheung, noted, “Exemestane worsens age-related decreases in bone mineral density by about three times, even in the setting of adequate calcium and vitamin D intake”.
It has been informed that the drug exemestane is considered to be wonder drug in India and most of the breast cancer patients are prescribed with the drug. It has been informed by the Head of Medical Oncology at Artemis Cancer Centre, Dr. Bhawna Sirohi that the drug works by reducing the production of oestrogen, which ultimately slows down the development of cancer cells or tumor.
Women are being encouraged to weigh their personal benefits and risks of having exemestane and then only decide whether or not they would like to go ahead with exemestane treatment.
French government has sent a strong message to...Read More
Emmanuel Macron has better support from French...Read More
Prominent Socialist Party leader Bertrand Delanoe...Read More
Presidential election candidate Emmanuel Macron has...Read More
Many personal care products available in the market...Read More
Centre-right Republican leaders will meet today to...Read More